ABBV Stock Summary and Trading Ideas (Abbvie | NYSE:ABBV)

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

Abbvie trades on the NYSE stock market under the symbol ABBV.

As of December 24, 2025, ABBV stock price climbed to $229.89 with 1,354,063 million shares trading.

ABBV has a beta of 0.28, meaning it tends to be less sensitive to market movements. ABBV has a correlation of 0.04 to the broad based SPY ETF.

ABBV has a market cap of $406.08 billion. This is considered a Mega Cap stock.

Last quarter Abbvie reported $16 billion in Revenue and $1.86 earnings per share. This beat revenue expectation by $189 million and exceeded earnings estimates by $.08.

In the last 3 years, ABBV traded as high as $244.81 and as low as $130.96.

The top ETF exchange traded funds that ABBV belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.

ABBV has outperformed the market in the last year with a price return of +32.5% while the SPY ETF gained +17.3%. However, in the short term, ABBV had mixed performance relative to the market. It has underperformed in the last 3 months, returning +4.0% vs +4.4% return in SPY. But in the last 2 weeks, ABBV shares have fared better than the market returning +3.1% compared to SPY +1.4%.

ABBV support price is $225.96 and resistance is $231.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABBV shares will trade within this expected range on the day.